| EPE0896 | Economic assessment and evaluation of Medically Assisted Therapy (MAT) services in six counties in Kenya | E-poster | Costing, cost effectiveness and affordability |
| OAE0302 | Long-acting HIV pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) in South Africa: cost-effective at what cost? | Oral abstract session with live Q&A | Costing, cost effectiveness and affordability |
| OAE0303 | Predicted HIV acquisition rates for cabotegravir versus TDF/FTC as PrEP in Brazil: effects of compulsory licensing | Oral abstract session with live Q&A | Costing, cost effectiveness and affordability |
| OAE0305 | Cost-effectiveness of the WHO-endorsed advanced HIV care package in Malawi | Oral abstract session with live Q&A | Costing, cost effectiveness and affordability |
| OALBE0603 | Costs and cost-effectiveness of immediate initiation of antiretroviral therapy upon diagnosis of HIV (Rapid Start) in the United States | Oral abstract session with live Q&A | Costing, cost effectiveness and affordability |
| TUPEE04 | The cost and intermediate cost-effectiveness of delivering U=U messaging to increase HIV testing among South African men | Poster exhibition | Costing, cost effectiveness and affordability |
| EPB0159 | Changes in symptoms of depression and anxiety over time in a cohort of people with HIV initiating HIV care in Cameroon | E-poster | Co-morbidities |
| EPB0160 | Factors associated with depression and ART adherence among young people living with HIV in Lilongwe, Malawi: a mixed-methods analysis | E-poster | Co-morbidities |
| EPB0161 | Global pattern and trends in Kaposi sarcoma incidence: a population-based study | E-poster | Co-morbidities |
| EPB0162 | Global prevalence of diabetes mellitus among ART-naïve adults living with HIV: a systematic review and meta-analysis | E-poster | Co-morbidities |